Bennett Urama1 *, Nkiru Anonyuo1 , Anthonia Ibeme1 , Uzoma Atu2 , Taiye Ologun2 , Babatunji Odelola3 and Adenike Adelanwa3
1 USAID Global Health Supply Chain Program-Procurement and Supply Management (GHSC-PSM) Project, Nigeria 2 National AIDS and STI Control Program (NASCP), Nigeria 3 United States Agency for International Development (USAID), NigeriaFulltext PDF
Background: Nigeria Federal Ministry of Health (FMOH) in 2018 adopted World Health Organization (WHO) recommended Dolutegravir (DTG) based Antiretroviral Therapy (ART) regimen Tenofovir/Lamivudine/Dolutegravir (TDF+3TC+DTG) as the preferred 1st line ART for adult and adolescent patients and recommended Tenofovir/Lamivudine/Efavirenz (TDF+3TC+EFV) for women who want to become pregnant. The FMOH also approved gradual transition of eligible adult and adolescent patients from TDF+3TC+EFV and Zidovudine/Lamivudine/Nevirapine (AZT+3TC+NVP) to TDF+3TC+DTG from November 2018. The objective of this analysis was to evaluate the trend in adult 1st line ART regimen following twenty months of implementation of the transition to TDF+3TC+DTG. Method: An analysis was conducted to review retrospective patients per regimen data from September/October 2018 to March/April 2020 reporting cycle. Data was retrieved from Nigeria Health Logistics Management Information System, exported to and analyzed with Microsoft Excel. Results: 85.5% of the patients on adult 1st line regimen were taking TDF+3TC+DTG, 13.3% were on TDF+3TC+EFV, no patient was taking AZT+3TC+NVP while 1.1% was on Abacavir based regimen as of end of April 2020. Conclusion: The evaluation shows that majority of adult and adolescent patients on 1st line ART have been transitioned to TDF+3TC+DTG in line with government recommendation.
HIV/AIDS; Antiretroviral therapy; kidney disease; Dolutegravir; Abacavir; Tenofovir; National HIV/AIDS Indicator and Impact Survey
Urama B, Anonyuo N, Ibeme A, Atu U, Ologun T, Odelola B, et al. Trend in Adult 1st Line Antiretroviral Therapy Regimen in Nigeria Antiretroviral Treatment Program: A 20-Months Retrospective Assessment (SeptemberOctober 2018 to March-April 2020 Reporting Cycle). Am J Med Public Health. 2020; 1(2): 1006..